Nira Madisi, MD
Endocrinology, Diabetes & Metabolism · Milford, DENPI 1952531899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,200 of the $23,289 with a category attached, or 73.9%. Amgen accounts for 91.1% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $20,810, more than ten times the $632 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $232.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$21K
- Medtronic$447
- Lilly USA, LLC$382
- Sanofi-aventis U.S. LLC$230
- Novo Nordisk$176
- Pulmonx Corporation$148
- plus $697 from 15 others
What the payments were for
- Speaking & faculty fees$17,20074%
- Travel & lodging$2,27710%
- Food & beverage$3,79616%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 35 | $21,209 |
| Medtronic(2 entities) | 6 | $447 |
| Lilly USA, LLC | 11 | $382 |
| Sanofi-aventis U.S. LLC | 8 | $230 |
| Novo Nordisk | 10 | $176 |
| Pulmonx Corporation | 1 | $148 |
| Halozyme Inc | 1 | $126 |
| AstraZeneca | 7 | $107 |
| Boehringer Ingelheim | 5 | $85 |
| Tandem Diabetes Care, Inc. | 1 | $75 |
| Mannkind Corporation | 3 | $66 |
| Insulet Corporation | 1 | $55 |
| BD | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| Abbott | 1 | $14 |
| Merck | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$20,534
- MINIMED 780G$325
- MOUNJARO$209
- CHARTIS CATHETER$148
- ZEPHYR DELIVERY CATHETER$148
- ZEPHYR ENDOBRONCHIAL VALVE$148
- PULMONX CHARTIS TABLET CONSOLE$148
- Prolia$136
- XGEVA$136
- XYOSTED$126
- TEPEZZA$123
- TZIELD$115
How this compares
$23,289 in reported general payments places this provider in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 126 | $217,624 |
| OzempicSemaglutide | 126 | $200,283 |
| JardianceEmpagliflozin | 117 | $148,933 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 31 | $71,340 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $53,142 |
| RybelsusSemaglutide | 23 | $49,078 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $29,225 |
| Novolog FlexpenInsulin Aspart | 86 | $29,142 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $24,299 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $20,932 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,478 |
| FarxigaDapagliflozin Propanediol | 13 | $18,993 |
| WegovySemaglutide | 11 | $16,627 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $15,906 |
| Repatha SureclickEvolocumab | 12 | $15,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy, Fiasp, Novolog | $176 | $291,016192 claims |
| Lilly USA, LLCMounjaro, Trulicity | $382 | $231,328139 claims |
| Boehringer IngelheimJardiance | $85 | $148,933117 claims |
| AmgenEvenity (2 Syringes) | $21,209 | $71,34031 claims |
| AstraZenecaFarxiga | $107 | $18,99313 claims |
| AbbVieSynthroid | $15 | $10,293103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Milford
- Ejaz MahmoodMilford$2K
- Lei Lei MinMilford$366
- Rithikaa EllangovanMilford$216
- Ripudaman HundalNewark$370K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
- Chitra ChoudharyDover$5K
- Ahmad ElayyanMillsboro$4K
- Sheetal BulchandaniNewark$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.